Tabrecta

AstraZeneca

Pharma

AZ, HutchMed get China nod for Orpathys for rare type of NSCLC

With Orpathys, AZ and HutchMed are the first in China to receive approval for a treatment against a rare form of NSCLC.

Kevin Dunleavy Jun 23, 2021 11:17am

Novartis panelists

New Novartis campaign message? Cancer continues during COVID-19

Feb 11, 2021 9:30am

Merck kgaa

Merck KGaA matches Novartis with FDA green light for Tepmetko

Feb 4, 2021 12:09pm

Novartis headquarters

Novartis beats out Merck KGaA with lung cancer drug Tabrecta

May 6, 2020 3:07pm